tetano
Editor, Senior Moderator
Adv Healthc Mater
. 2025 Jun 16:e2501869.
doi: 10.1002/adhm.202501869. Online ahead of print. Identification of Pan-Coronavirus Neutralizing Aptamers Through CRISmers Targeting the Conserved Fusion Peptide
Ju Zhang[SUP] 1 2 3 [/SUP], Airu Zhu[SUP] 4 [/SUP], Shixian Wei[SUP] 1 2 3 5 [/SUP], Yongshi Shi[SUP] 3 [/SUP], Canjie Chen[SUP] 4 [/SUP], Ting Huang[SUP] 4 6 [/SUP], Tian Tang[SUP] 4 [/SUP], Jingxian Zhao[SUP] 4 6 [/SUP], Yushan Cai[SUP] 2 3 [/SUP], Chunsheng Han[SUP] 1 5 [/SUP], Jincun Zhao[SUP] 4 6 7 [/SUP], Yu Wang[SUP] 2 3 8 [/SUP]
Affiliations
A series of coronavirus outbreaks emphasize the necessity to develop pan-coronavirus therapeutics. Previously, the CRISmers system is developed, a Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated proteins (CRISPR/Cas)-mediated cellular screening platform for the identification of RNA aptamers. In this study, CRISmers are applied to target the fusion peptide (FP) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a conserved region across coronavirus genera, with E.coli serving as the screening host. From this approach, a lead aptamer, #FP-10 is identified, which demonstrates potent pan-coronavirus neutralization activity against multiple SARS-CoV-2 variants and alphacoronaviruses (HCoV-229E and HCoV-NL63), demonstrating its potential for development into a broad-spectrum therapeutic candidate.
Keywords: CRISPR/Cas; CRISmers; Coronaviruses; RNA aptamers; SARS‐CoV‐2; fusion peptide; synthetic biology.
. 2025 Jun 16:e2501869.
doi: 10.1002/adhm.202501869. Online ahead of print. Identification of Pan-Coronavirus Neutralizing Aptamers Through CRISmers Targeting the Conserved Fusion Peptide
Ju Zhang[SUP] 1 2 3 [/SUP], Airu Zhu[SUP] 4 [/SUP], Shixian Wei[SUP] 1 2 3 5 [/SUP], Yongshi Shi[SUP] 3 [/SUP], Canjie Chen[SUP] 4 [/SUP], Ting Huang[SUP] 4 6 [/SUP], Tian Tang[SUP] 4 [/SUP], Jingxian Zhao[SUP] 4 6 [/SUP], Yushan Cai[SUP] 2 3 [/SUP], Chunsheng Han[SUP] 1 5 [/SUP], Jincun Zhao[SUP] 4 6 7 [/SUP], Yu Wang[SUP] 2 3 8 [/SUP]
Affiliations
- PMID: 40522066
- DOI: 10.1002/adhm.202501869
A series of coronavirus outbreaks emphasize the necessity to develop pan-coronavirus therapeutics. Previously, the CRISmers system is developed, a Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated proteins (CRISPR/Cas)-mediated cellular screening platform for the identification of RNA aptamers. In this study, CRISmers are applied to target the fusion peptide (FP) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a conserved region across coronavirus genera, with E.coli serving as the screening host. From this approach, a lead aptamer, #FP-10 is identified, which demonstrates potent pan-coronavirus neutralization activity against multiple SARS-CoV-2 variants and alphacoronaviruses (HCoV-229E and HCoV-NL63), demonstrating its potential for development into a broad-spectrum therapeutic candidate.
Keywords: CRISPR/Cas; CRISmers; Coronaviruses; RNA aptamers; SARS‐CoV‐2; fusion peptide; synthetic biology.